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is a rare disease characterized by C1-esterase inhibitor
(C1-INH) deficiency, resulting in periodic attacks of acute
edema, which can be life-threatening if they occur in the
upper airway. No head-to-head comparisons of different
treatment options for acute HAE attacks are available.
Because immediate symptom relief is critical for potentially
life-threatening laryngeal attacks, it is important to deter-
mine the treatment option that provides optimal treatment
response. Objective: Review and compare data from clinical
studies that evaluated the efficacy and safety of treatments
for laryngeal HAE attacks. Methods: We conducted an indi-
rect comparison of clinical outcomes from prospective
studies for treatment of 881 acute laryngeal attacks with
plasma-derived C1-INH concentrate (pdC1-INH) at fixed
doses (500 or 1000 U) or a body weight-adjusted dose (20
U/kg), recombinant C1-INH concentrate at a fixed dose
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567(30 mg), or ecallantide (30 mg). Comparisons included time
to onset of symptom relief and need for re-dosing or emer-
gency procedures. Results: The median time to onset of
symptom relief ranged between 15 min and approximately
2 h, and was shortest with body weight-adjusted doses of
pdC1-INH. The proportion of laryngeal attacks with
re-dosing ranged between 0% and 72%. No re-dosing
was needed after treatment with a single body weight-
adjusted dose of pdC1-INH (48 attacks). Conclusions:
Available data suggest that among different HAE treat-
ments, body weight-adjusted pdC1-INH (20 U/kg) provides
the most reliable treatment response for treatment of laryn-
geal HAE attacks.  2016 The Authors. Published by
Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
, Keywords—C1-INH; efficacy; HAE; laryngeal;
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INTRODUCTION
Hereditary angioedema (HAE) due to C1-esterase inhib-
itor (C1-INH) deficiency (HAE–C1-INH, hereafter called
HAE) is a rare autosomal dominant disorder caused by
reduced expression of normal C1-INH (type I HAE) or
expression of less functional C1-INH (type II HAE)
(1,2). Patients with HAE experience intermittent
episodic swellings that may affect the skin or
568 K. Bork et al.gastrointestinal tract and are potentially life-threatening
in case of laryngeal attacks. Clinical symptoms of laryn-
geal attacks include hoarseness, stridor, dyspnea, the
feeling of having a lump in the larynx, dysphagia, and
voice change (3). Although laryngeal attacks are rare
(approximately 1% of HAE attacks), at least 50% of
patients with HAE experience a laryngeal attack at least
once in their lifetime (3). Mortality of 14% to 33% due
to untreated and unrecognized laryngeal attacks has
been reported, highlighting the importance of early diag-
nosis of HAE and providing patients with appropriate
treatment for potentially life-threatening HAE attacks
(4,5).
International consensus guidelines recommend
plasma-derived C1-INH concentrate (pdC1-INH;
Berinert [CSL Behring, King of Prussia, PA] or
Cinryze [Shire, Lexington, MA], at fixed doses of
1000 U and body weight-adjusted doses of 20 U/kg)
or recombinant C1-INH concentrate (rhC1-INH,
Ruconest [Salix Pharmaceuticals, Inc., Raleigh, NC]),
bradykinin B2 receptor antagonist icatibant (Firazyr
[Shire]), or kallikrein inhibitor ecallantide (Kalbitor
[Dyax Corp., Burlington, MA]) for the treatment of acute
HAE attacks (6–10).
To date, no head-to-head comparisons of the efficacy
and safety of different treatment options for acute HAE
attacks are available. Because fast response to treatment
is especially important for potentially life-threatening
laryngeal attacks, we reviewed and compared available
data from clinical studies on treatment of laryngeal
attacks that evaluated the efficacy and safety of different
treatment options for the rare but potentially life-
threatening cases of laryngeal attacks. ComparisonsTable 1. Treatment Options for Acute HAE Attacks
Trade Name (Manufactured for) Active Substance
Berinert (CSL Behring) Human pasteurized,
nanofiltered pdC1-INH
Cinryze (ViroPharma) Human pasteurized,
nanofiltered pdC1-INH
Ruconest (Pharming) rhC1-INH
Firazyr (Shire) Icatibant, bradykinin 2
receptor antagonist
Kalbitor (Dyax) Ecallantide, kallikrein inhibitor
HAE = hereditary angioedema; pdC1-INH = plasma-derived C1-esteras
hibitor concentrate; US = United States.
* In case of insufficient clinical response, an additional dose can be adm
24 h.
† In case of insufficient relief or recurrence of symptoms, additional injec
3 injections should be administered within 24 h.
‡ If attack persists, an additional dose may be administered within 24include efficacy in terms of treatment response and
need for re-dosing.
METHODS
Search Methods and Data Collection
Reports on the treatment of laryngeal attacks with licensed
HAE treatments (see Table 1) were identified by a system-
atic database search in PubMed and EMBASE in May
2015. The full search strategies are provided in Appendix
1 (available online). In addition, we searched the Internet,
specifically, publications listed in clinicaltrials.gov for
completed HAE studies (as of April 2015) and Web sites
of regulatory agencies. Titles and abstracts from electronic
databases and publications associated with completed
HAE studies in clinicaltrials.gov were examined for eligi-
bility.We obtained the full text of all relevant records.Data
extracted on treatment of laryngeal attacks in patients with
HAE type I or IIwith different treatments included efficacy
endpoints, the need for re-dosing, and the need for emer-
gency procedures (e.g., intubation).Assessment of Risk of Bias
The risk of selective outcome reporting was assessed
based on the process described by Dwan et al. for all rele-
vant studies identified in the systematic literature search
(11). For each study, we extracted results for the
outcomes used in this comparison of treatment options
for laryngeal attacks. Outcomes that were not fully
reported but may have been assessed based on the
reported methods were highlighted. The assessment ofLicensed for
Recommended Dose & Route
of Administration
Europe: acute treatment &
short-term prophylaxis
US: acute treatment only
20 U/kg, intravenous
Europe: acute treatment &
prophylaxis
US: prophylaxis only
1000 U, intravenous
Acute treatment (not for
treatment of laryngeal
attacks in the US)
50 U/kg,* intravenous
($84 kg: 4200 U)
Acute treatment 30 mg,† subcutaneous
Acute treatment (US only) 3  10 mg,‡ subcutaneous
e inhibitor concentrate; rhC1-INH = recombinant C1-esterase in-
inistered. Not more than two doses should be administered within
tionsmay be administered at intervals of at least 6 h. Nomore than
h.
Comparison of Treatments for Acute HAE Attacks 569selective outcome reporting bias for each study was based
on the published results.
Data Analysis
The following treatment options were compared: pdC1-
INH at fixed doses of 500 or 1000 U or at body weight-
adjusted doses of 20 U/kg, rhC1-INH fixed doses of
2100 U or at body weight-adjusted doses of 50 U/kg,
30 mg of icatibant, and 30 mg of ecallantide.
Laryngeal attacks are potentially life-threatening, and
effective treatments are available for more than 30 years
in some countries. Thus, it is generally considered uneth-
ical to include laryngeal attacks in placebo-controlled
studies of HAE. Except for the treatment of five laryngealTable 2. Patient-reported Time to Onset of Symptom Relief for La
Drug Endpoint
Question A
Assessm
pdC1-INH (Berinert)* Onset of symptom relief
(first of 2 consecutive
reports)
‘‘Taking into ac
symptoms,
confident th
attack is sta
improve?’’
Time to first signs of
symptom resolution
or end of symptom
progression
Assessed
consecutive
least every 6
by patient in
during office
by telephon
pdC1-INH (Cinryze) Time to unequivocal
relief (first of 3
consecutive reports)
Symptoms (de
site): ‘‘absen
present befo
‘‘present, sy
better’’ or ‘‘a
now and be
rhC1-INH Time to first onset of
relief of symptoms
(first of 2 consecutive
reports)
VAS decrease
by $ 20 mm
compared w
baseline for
eligible loca
(abdominal,
urogenital, o
pharyngeal-
laryngeal, o
peripheral)
Icatibant Patient-reported time to
initial symptom
improvement (first
report)
Time at which
improvemen
symptoms w
noticed
Ecallantide Beginning of
improvement (first
report)
Overall respon
assessment
better’’ or ‘‘a
better or res
HAE = hereditary angioedema; pdC1-INH = plasma-derived C1-esteras
hibitor concentrate; VAS = visual analog scale.
* Definition used in the I.M.P.A.C.T.2 study.attacks in a placebo-controlled study of icatibant, data on
the treatment of laryngeal attacks are available only from
open-label studies (12).
All studies used patient-reported outcomes to assess
onset of symptom relief, although time to onset of
symptom relief was not the primary endpoint in all
studies, and definitions varied for studies with different
drugs [see Table 2 (13–19)]. As secondary efficacy
endpoint, some studies assessed the time to complete
resolution, others the duration of attacks, the time to
minimal symptoms, or the time to almost complete
symptom relief. Comparisons of time to complete
resolution of laryngeal attacks with different
treatments need to be interpreted with caution because
assessments were even more diverse between differentryngeal Attacks–Definitions and Assessments
sked/
ent Time Points Reference
count all
are you
at the
rting to
Up to 24 h after
administration (20
time points; every
15 min for the first
2 h, every 30 min for
the next 2 h, and at 5,
6, 7, 8, 12, 16, 20,
and 24 h after
administration)
Craig et al. (13),
Bernstein et al. (14)
ly at
months
terviews
visits or
e
Patients were issued a
patient diary and
asked to record data
on symptom
resolution of HAE
attacks
Data on file
fining
t but
re’’ or
mptoms
bsent
fore’’?
Up to 4 h after
administration or
substantial relief (16
time points; every
15 min)
Riedl et al. (15)
ith
any
tion
rofacial-
r
Up to 48 h after
administration (11
time points; baseline,
15 and 30 min, and 1,
2, 4, 8, 12, 16, 24,
and 48 h after
administration)
Moldovan et al. (16)
initial
t of
as
Patients were asked to
record the date and
time when they felt
their symptoms
started to improve
Cicardi et al. (17),
Malbra´n et al. (18)
se
: ‘‘a little
lot
olved’’
Up to 24 h after
administration (5
time points; 1, 2, 3, 4,
and 24 h after
administration)
Sheffer et al. (19)
e inhibitor concentrate; rhC1-INH = recombinant C1-esterase in-
570 K. Bork et al.studies and treatments than assessments of onset of
symptom relief.
Due to the heterogeneity of open-label studies and due
to variations in the definitions of efficacy endpoints, a
meta-analysis (i.e., an adjusted indirect comparison based
on differences between active treatment and placebo) was
not possible. However, it is extremely unlikely that HAE
treatments for laryngeal attacks will ever be directly
compared in a head-to-head analysis using validated
‘‘commonground’’ criteria for the assessment of treatment
response (20). Therefore, we performed a descriptive
comparison of the available efficacy data on the treatment
of laryngeal attacks with different drugs. Furthermore, the
percentages of laryngeal attacks treated with additional
doseswere compared descriptively; 95%confidence inter-
vals (CIs) were calculated from available data.
Differences in treatment response (in terms of time to
onset of symptom relief and time from start of attack to
complete resolution of symptoms) between treatment
with pdC1-INH at fixed doses of 500 or 1000 U and
body weight-adjusted doses of 20 U/kg were assessed
descriptively, and by a Wilcoxon test.
RESULTS
Overview of Studies
The search strategy identified 196 articles, eight of which
were identified as eligible for the comparison of efficacy
for the treatment of laryngeal attacks. In addition, four
relevant articles and reports were identified based on pub-
lications listed in clinicaltrials.gov for completed HAE
studies and on Web sites of regulatory agencies.
A tabular overview of the 12 different eligible studies
or analyses, which included a total of 881 treated laryn-
geal attacks, is provided in Table 3 (12,13,15–19,21–
25). Even though some studies were controlled studies,
laryngeal attacks were excluded from randomized
treatment and were treated open-label, except for three
attacks treated with icatibant during the placebo-
controlled part of study FAST-3 (two laryngeal attacks
were treated with placebo in this study) (12).Risk of Bias
The risk of selective outcome reporting was considered
low for most of the included studies and analyses
[Table 4 (13,15–19,21–25)]. It should be noted that the
focus of publications was often on other attack
locations that were included in double-blind, randomized
parts of the studies. Potentially life-threatening laryngeal
attacks were generally only treated open-label and were
therefore not always fully assessed and reported.Efficacy of Different Treatments (Per-attack Analysis)
The median time to onset of symptom relief after treat-
ment of laryngeal attacks was shortest with body
weight-adjusted doses of pdC1-INH and ranged between
15 min and approximately 2 h for the different drugs
(Figure 1). Fast onset of symptom relief was generally
achieved with all treatment options and was reported
within 1 h after the start of treatment for 60% to 100%
of laryngeal attacks, and within 4 h after the start of treat-
ment for 77% to 100% of laryngeal attacks [Table 5
(12,13,15,16,19,21,22,24)].
The median time from start of attacks to complete res-
olution of laryngeal attacks ranged between 9 and 16 h,
and the median time from treatment to complete resolu-
tion generally ranged between 3 and 12 h. However,
comparisons between treatments should be interpreted
with caution due to differences in the definition of time
to complete resolution.
The time between onset of symptoms and start of treat-
ment was stipulated in the study protocol for several
studies (between 4 and 8 h, see Table 3), but the actual
times to treatment are only rarely published. The median
time to treatment for laryngeal attacks was 3.15 h in the
I.M.P.A.C.T.2 study with the pdC1-INH Berinert, and
53% of laryngeal attacks were treated within # 4 h in
studies with the pdC1-INH Cinryze (13,15).
Efficacy of Different Doses of pdC1-INH
Most patients in the pdC1-INH body weight-adjusted and
fixed-dose groups experienced onset of symptom relief
within 4 h after injection (Table 5). In a per-patient analysis
of laryngeal attacks treatedwith thepdC1-INHBerinert, the
median average time to onset of symptom relief (95% CI)
was 26.1 min (18.6–41.5) in the body weight-adjusted
dose group and 42.5 min (30.0–60.0) in the fixed-dose
group, with the difference being significant (p = 0.019),
and with no significant differences between fixed doses of
500 vs. 1000 U pdC1-INH. This difference in time to onset
of symptom relief between the body weight-adjusted and
the fixed-dose group was also observed in a per-attack
Kaplan-Meier analysis (Figure 2). The median average
time from start of attack to complete resolution (95% CI)
in a per-subject analysis of laryngeal attacks treated with
the pdC1-INH Berinert was 10.5 h (5.1–29.4) in the body
weight-adjusted dose group and 17.8 h (16.0–27.0) in the
fixed-dose group. Also, this difference was significant
(p = 0.037), with no significant difference between the
500 and 1000 U dose group. However, the aforementioned
differences in definitions of endpointsmake the comparison
of the studies difficult; therefore, the results have to be
considered with caution.
Table 3. Overview of Included Studies
Drug; Study Study Design Dose Regimen
Efficacy Outcomes for
Treatment of Laryngeal
Attacks Notes
Patients with
Laryngeal Attacks
Number of
Laryngeal Attacks
Berinert (pdC1-INH,
CSL Behring,
Marburg, Germany)
241
I.M.P.A.C.T.2 (13) Open-label 20 U/kg Time from start of
treatment to onset of
symptom relief, time
to complete
resolution of HAE
symptoms
No restrictions for time
between onset of an
attack and start of
treatment (median:
3.15 h), no
stipulations
regarding re-dosing
16, HAE type I or II 48
Bork & Barnstedt (21) Case collection 500 or 1000 U Time to first signs of
symptom resolution
or end of symptom
progression,
duration of laryngeal
edema from first
symptoms to
attainment of
normality
Second 500-U injection
was administered if
symptoms did not
resolve within 30 to
60 min; if a second
dose was necessary
in 3 consecutive
attacks, patients
received 1000 U for
all subsequent
attacks
42, HAE type I or II 193
Cinryze (pdC1-INH,
ViroPharma,
Brussels, Belgium)
267
LEVP 2006-1 (15) Open-label 1000 U Time to unequivocal
relief (3 consecutive
reports), clinical relief
(1 or more
assessment of
improvement
followed by
discharge),
beginning of relief
(first assessment of
improvement)
Treatment within 4 h
from onset of attack
(not always
possible); re-dosing
after 60 min if there
was no substantial
relief
37, HAE type I or II 84
Pooled analysis (15)* Placebo-controlled†/
open-label
1000 U None* See LEVP 2006-1;
determination of
clinical effectiveness
was confined to
study LEVP 2006-1
because data on time
to attack resolution
were not
systematically
85, HAE type I or II 267
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Table 3. Continued
Drug; Study Study Design Dose Regimen
Efficacy Outcomes for
Treatment of Laryngeal
Attacks Notes
Patients with
Laryngeal Attacks
Number of
Laryngeal Attacks
collected in the other
studies
Ruconest (rhC1-INH,
conestat alfa)
65
1304-01-OLE (16) Open-label 2100 U Time to first onset of
symptom relief; time
to ‘‘minimal’’
symptoms
Treatment within 6 h
(presentation within
5 h of onset with an
overall VAS severity
score of at least
50 mm and no
spontaneous
regression after 1 h);
up to 2 additional
vials (2100 U each)
could be
administered within
4 h
24, HAE type I or II 45‡
Pooled analysis (22)§ Open-label 50 U/kg or 2100 U See above (1304-01-
OLE)
See above (1304-01-
OLE)
25, HAE type I or II 33
Firazyr (icatibant) 88
FAST-1 and FAST-2
(17)
Placebo-controlled†/
open-label
30 mg Median time to initial
symptom
improvement
(patient-reported)
Treatment within 6 h;
rescue medication
(C1-INH, antiemetic
agents, or opiates)
withheld for as long
as possible (ideally 8
or 9 h after initial
treatment)
11, HAE type I or II 11
FAST-1 OLE (18) Open-label 30 mg Median time to initial
symptom
improvement
(patient-reported),
change in
investigator-
assessed symptom
score severity
Further icatibant
injections permitted
if symptoms
worsened within 48 h
of the initial treatment
(maximum of 3 doses
at least 6 h apart).
Rescue medication
for relief of any
symptom permitted.
19, HAE type I or II 37
FAST-2 OLE (23) Open-label 30 mg Median time to initial
symptom
improvement
(patient-reported),
change in
investigator-
See above (FAST-1) 10, HAE type I or II 30
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Table 3. Continued
Drug; Study Study Design Dose Regimen
Efficacy Outcomes for
Treatment of Laryngeal
Attacks Notes
Patients with
Laryngeal Attacks
Number of
Laryngeal Attacks
assessed symptom
score severity,
patient-assessed
symptom scores for
difficulty swallowing
and voice change
FAST-3 incl. OLE (12) Placebo-controlled†/
open-label
30 mg Median times to 50%
reduction in 5-
symptom composite
VAS score, onset of
primary symptom
relief, reduction in
laryngeal symptom
score, almost
complete symptom
relief, and initial
symptom
improvement (patient
and investigator), any
reduction in laryngeal
VAS score, and any
reduction in patient-
and investigator-
assessed laryngeal
symptom score
Treatment within 6 h
(severe laryngeal
attacks were always
treated open-label);
no stipulations
regarding re-dosing
reported
21, HAE type I or II 21
Pooled analysis
(FAST-1, -2, and
-3, incl. OLE;
interim) (24,25)
Open-label 30 mg Time to first symptom
improvement
(according to
patient); Clinical
Global Improvement
as assessed by the
investigator
See above 60, HAE type I or II 60
Kalbitor (ecallantide) 220
Pooled analysis
(EDEMA2,
EDEMA3,
EDEMA4, DX-88/
19) (19)
Placebo-controlled†/
open-label
30 mg Mean Symptom
Complex Severity
(MSCS) score,
Treatment Outcome
Score (TOS),
beginning of
improvement, onset
of sustained
improvement, onset
of significant
improvement
Treatment within 8 h
(4 h in EDEMA2) of
onset of a moderate
or severe attack (no
restrictions on time
or intensity in DX-88/
19); Re-dosing:
additional open-label
dose within 4 h for
severe upper airway
compromise
98, HAE type I or II 220
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574 K. Bork et al.Need for Re-dosing or Emergency Procedures
Across different treatments and studies, the proportion of
laryngeal attacks with re-dosing ranged between 0% and
72% (Figure 3). No re-dosing was needed for laryngeal
attacks treated with body weight-adjusted pdC1-INH
(20 U/kg). Of the laryngeal attacks treated with fixed
doses of pdC1-INH (500 or 1000 U), 0% to 62% of
attacks required re-dosing. The highest proportion of
attacks with re-dosing was reported for laryngeal attacks
treated with rhC1-INH at a fixed dose of 2100 U (72%)
(16). With icatibant, the proportion of laryngeal attacks
with re-dosing in the open-label extension phases of
FAST-1 and FAST-2 ranged between 7% and 14%, and
with ecallantide, the proportion of laryngeal attacks
with re-dosing was 10%.
Three patients were intubated, one had received a fixed
dose of 1000 U pdC1-INH, onewas treated with icatibant,
and one was treated with ecallantide (15,17,19). No
emergency procedures were reported for any of the
other laryngeal attacks treated.
DISCUSSION
Potentially life-threatening laryngeal edema represents a
continuous threat to patients with HAE. Laryngeal attacks
mostly occur spontaneously and without warning, and can
even be thefirst clinical symptomofHAE (26). Despite the
availability of targeted and effective therapies for the
emergency management of HAE attacks, patients with
HAE still die from untreated laryngeal attacks (26–28).
Due to the danger of asphyxiation, it is vital that a
laryngeal edema be treated effectively as early as
possible, prior to reaching its maximum development.
Emergency procedures such as intubation or
tracheotomy can be avoided with treatment that provides
fast onset of symptom relief (5). Treatments for laryngeal
attacks should therefore ensure rapid treatment response
with a single dose, as the need for re-dosing and associated
progression of the laryngeal edemamay endanger patients
withHAE experiencing an acute laryngeal attack. Because
a large part of the medical community lacks knowledge of
the rare disorder of HAE, it is recommended that patients
have an emergency supply of an effective HAE treatment
at home or with them when they travel (29).
As no head-to-head comparisons of the efficacy of
different treatment options for acute HAE attacks are
available to date, we reviewed and compared available
data from clinical studies on treatment of laryngeal
attacks to assess potential differences in efficacy and
need for re-dosing. The available data suggest that body
weight-adjusted doses of 20 U/kg pdC1-INH provide
the shortest median time to onset of symptom relief
(15 min), followed by approximately 30 to 45 min with
Table 4. Reporting of Outcome Measures Used for Descriptive Comparisons and Assessment of Selective Outcome Reporting
Drug; Study/Publication
Outcome
Risk of Bias Due to
Selective Outcome
Reporting
Time to Onset of Symptom Relief
Time to
Complete
Resolution
Time from
Start of Attack
to Resolution Re-dosing
Emergency
Procedures
Median
(95% CI)
Proportion
# 1 h
Proportion
# 4 h
Berinert (pdC1-INH, CSL Behring, Marburg, Germany)
I.M.P.A.C.T.2 (13) U U U U U U U No risk (all outcomes
reported)
Bork & Barnstedt (21) U* U U – U U U No risk (all outcomes
reported)
Cinryze (pdC1-INH, ViroPharma, Brussels, Belgium)
LEVP 2006-1 (15) U U U – – U† U† No risk (all assessed
outcomes reported)
Pooled analysis (15)‡ – – – – – U U No risk (all assessed
outcomes reported)
Ruconest (rhC1-INH, conestat alfa)
1304-01-OLE (16) B – B B – B – High risk (partial reporting,
times to onset of
symptom relief, and
complete resolution
reported for only 20 of at
least 45 laryngeal
attacks [no explanation
for missing data]; no
total number of laryngeal
attacks; proportion of
patients with relief within
4 h only reported by
attack number for first
five attacks; no number
of attacks reported for
re-dosing, just
percentage)
Pooled analysis (22)§ U – U U – U U Not applicable (report from
regulatory agency, no
original publication)
Firazyr (icatibant)
FAST-1 OLE (18) B – – – – U U Low risk (partial reporting
of time to onset of
symptom relief [no
overall results, just
subgroups by attack
number, legend of figure
unclear/incomplete])
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Table 4. Continued
Drug; Study/Publication
Outcome
Risk of Bias Due to
Selective Outcome
Reporting
Time to Onset of Symptom Relief
Time to
Complete
Resolution
Time from
Start of Attack
to Resolution Re-dosing
Emergency
Procedures
Median
(95% CI)
Proportion
# 1 h
Proportion
# 4 h
FAST-2 OLE (23) B B U – – U B (Rescue
medication)
Low risk (partial reporting
of time to onset of
symptom relief [no
overall results, just
subgroups by attack
number, legend of figure
unclear/incomplete]; no
reporting on emergency
procedures although it
can be assumed that it
was assessed)
FAST-1 and
FAST-2 (17)
B† –† – – – U U Low risk (only partial
reporting for time to
onset of relief)
FAST-3 incl.
OLE (12)
U – – U – – B (Rescue
medication)
Low risk (no reporting on
re-dosing and
emergency procedures
although it can be
assumed that it was
assessed)
Pooled analysis
(24,25)k
U U – – – U B (Rescue
medication)
Not applicable (reports
from regulatory
agencies, no original
publication)
Pooled analysis
(19){
U – U U – U U Low risk (it can be assumed
that data on proportion
of patients with onset of
symptom relief of # 1 h
are available; however,
not a defined outcome in
this study)
CI = confidence interval; OLE = open-label extension; pdC1-INH = plasma-derived C1-esterase inhibitor concentrate; rhC1-INH = recombinant C1-esterase inhibitor concentrate;
SD = standard deviation.
U indicates full reporting;B indicates partial reporting; - indicates no reporting.
* Data on file for median (95% CI) by dose (500 or 1000 U), publication reports mean (SD) for all attacks (irrespective of dose).
† Included in pooled analysis.
‡ Pooled analysis of 4 studies (LEVP 2005-1/A and B, LEVP 2006-1, and LEVP 2006-4).
§ Pooled analysis of interim data from studies 1205-01-OLE (50 U/kg) and 1304-01-OLE (2100 U).
k Pooled analysis of interim data from studies FAST-1, -2, and -3, incl. OLEs.
{ Pooled analysis of 4 studies (EDEMA2, EDEMA3, EDEMA4, and DX88/19).
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subgroup: FAST-3 OLE (N=21)
500 U (N=48)
Figure 1. Median time to onset of symptom relief for laryn-
geal attacks (per-attack analysis). The whiskers show the
95% confidence intervals. N = Number of attacks;
OLE = open-label extension; pdC1-INH = plasma-derived
C1-esterase inhibitor concentrate; rhC1-INH = recombinant
C1-esterase inhibitor concentrate. aData on file. bTwo of 84
attacks did not have time to beginning of unequivocal relief
reported. cNo confidence intervals available. dIncluding
data from 27 attacks treated in FAST-1, 12 attacks treated
in FAST-2, and 21 attacks treated in FAST-3. eFour of 220 at-
tacks did not have beginning of improvement reported.
Comparison of Treatments for Acute HAE Attacks 577fixed doses of pdC1-INH or icatibant, and approximately
1.5 h with ecallantide and 2 h with rhC1-INH. No
re-dosing was needed for laryngeal attacks treated with
body weight-adjusted doses of 20 U/kg pdC1-INH.
Whereas in one study, a second dose was needed for
30% of laryngeal attacks treated with 500 U pdC1-INH,
a single dose was sufficient for attacks treated with
1000 U. In another study, using a different pdC1-INH,
62% of the attacks treated with 1000 U required re-
dosing. Therefore, the available data suggest that a
body weight-based dosing regimen of 20 U/kg pdC1-
INH provides faster and more reliable treatment response
than fixed doses of 500 or 1000 U pdC1-INH.
More than 70% of laryngeal attacks treated with rhC1-
INH at a fixed dose of 2100 U needed a second dose to
achieve symptom relief. With icatibant or ecallantide,
the percentage of laryngeal attacks with re-dosing (be-
tween 7% and 14%) was between that observed with0
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Figure 2. Time to onset of symptom relief for different doses
of pdC1-INH (per-attack analysis). N = Number of attacks.
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±
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Icatibant 
rhC1-INH 
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Figure 3. Need for re-dosing after laryngeal attacks. N =
Number of attacks; OLE = open-label extension; pdC1-
INH = plasma-derived C1-esterase inhibitor concentrate;
rhC1-INH = recombinant C1-esterase inhibitor concentrate.
aFor twoof 267 attacks, dosingdatawere not available. bAlth-
ough the total number of laryngeal attacks was not provided
in Moldovan et al. and may be higher, it was reported that 45
laryngeal attacks were treated among the first five attacks of
each patient (16). Re-dosing frequency was calculated based
on this number and deviates from the number of attacks
requiring re-dosing given in Moldovan et al. (72%) due to
rounding (16).
578 K. Bork et al.body weight-adjusted doses of pdC1-INH (no re-dosing)
and that observed with rhC1-INH. Emergency procedures
like intubation were reported for only three of 881 treated
laryngeal attacks.
Overall, the descriptive comparison of available data
from clinical studies on treatment of laryngeal HAE
attacks suggests that pdC1-INH at a single body
weight-adjusted dose of 20 U/kg provides the most reli-
able treatment response. If pdC1-INH is not available,
all other treatment options analyzed in this study are
also appropriate for the treatment of laryngeal attacks
and provide rapid and reliable relief. However, it should
be noted that differences in efficacy or need for
re-dosing in this descriptive comparison may be biased
by methodological differences between studies.
Limitations
Due to the lack of data from placebo control arms (consid-
ered unethical for potentially life-threatening laryngeal
attacks) and the heterogeneity of studies, a meta-
analysis (i.e., an adjusted indirect comparison) of different
treatments for laryngeal attacks based on the treatment
response relative to placebo was not possible. In addition
to the inherent problems of a descriptive across-study
comparison, other limitations of this comparison include
differences in study design and definitions of efficacy end-
points. For example, some study protocols stipulated
re-dosing at a specific time when symptom relief had
not been reported (e.g., after 1 h for Cinryze), whereas
other study protocols did not specify a time point forre-dosing (e.g., I.M.P.A.C.T.2 study with Berinert). Dif-
ferences in the percentage of attacks with reported time
to onset of symptom relief between fixed doses of 1000
U of the pdC1-INH products Cinryze and Berinert
(Figure 2) should be interpreted with caution because
they may be confounded by differences in study design
and timing of assessments (see Tables 2 and 3). Time to
onset of symptom relief and complete resolution may
also be biased by different times from start of an attack
to treatment, which are only rarely reported. It should
also be noted that the high rate of re-dosing and the rela-
tively long time to onset of symptom relief observed
with rhC1-INH may be biased by the fact that there was
no clear distinction between laryngeal and facial attacks
in the studies with rhC1-INH; all ‘‘orofacial-pharyngeal-
laryngeal’’ attacks were included in the analysis (16).
CONCLUSIONS
Due to the differences in study design and limitations of
descriptive cross-study comparisons, the results of this
study can only be hypothesis-generating. A prospective
study comparing different treatment options, using vali-
dated ‘‘common ground’’ criteria for efficacy assess-
ments, and thoroughly investigating differences that
may exist between treatments for laryngeal attacks
regarding efficacy would be ideal, but is extremely
unlikely to be conducted given the complexity of a
head-to-head trial in a clinical emergency condition
such as an acute laryngeal attack and given the small
size of the population of HAE patients. Therefore,
clinician-driven consensus recommendations can only
resort to the comparative value of the available data on
treatment of laryngeal attacks. Currently available clin-
ical evidence suggests that pdC1-INH at a body weight-
adjusted dose of 20 U/kg should be considered as the
preferred treatment choice for treatment of acute laryn-
geal HAE attacks to ensure optimal treatment response.
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1. Why is the topic important?
Acute attacks of hereditary angioedema (HAE) can be
life-threatening if they occur in the upper airway. Prompt
and effective therapies are available and can help avoid
emergency procedures such as intubation or tracheotomy
and decrease the rate of mortality among patients with this
condition.
2. What does this study attempt to show?
We reviewed and compared data from clinical studies
that evaluated the efficacy and safety of different treat-
ment options for acute laryngeal HAE attacks in terms
of time to onset of symptom relief, need for re-dosing,
and need for emergency procedures. Treatment options
included plasma-derived C1-esterase inhibitor concen-
trate (pdC1-INH), recombinant C1-esterase inhibitor
concentrate, icatibant, and ecallantide.
3. What are the key findings?
Of the different treatment options, pdC1-INH at body
weight-adjusted doses of 20 U/kg provides the most reli-
able response. However, our findings indicated that, if
pdC1-INH is not available, all other options are also
appropriate in providing rapid and reliable relief.
4. How is patient care impacted?
A prospective study comparing different treatment op-
tions would be ideal, but is extremely unlikely to be con-
ducted given the complexity of a head-to-head trial in a
clinical emergency condition such as an acute laryngeal
attack and the small size of the population of HAE pa-
tients. Because clinician-driven consensus recommenda-
tions can therefore only resort to the comparative value
of the available data, our comparison provides useful in-
formation on the emergency management of laryngeal at-
tacks of HAE. It aims at raising awareness of HAE, the
risk of asphyxiation during an (untreated) laryngeal
attack, and the availability of safe and effective therapies
among health care professionals and patients.
APPENDIX 1
EMBASE search criteria:
#1 ‘hereditary angioedema’/exp OR ‘hereditary angioe-
dema’
#2 ‘larynx’/exp
#3 ‘laryngeal’
#4 ‘larynx’
#5 #2 OR #3 OR #4
#6 #1 AND #5
#7 ‘ecallantide’/exp
#8 ‘c1 inhibitor’/exp
#9 ‘icatibant’/exp
#10 ‘serping1 protein human’
#11 ‘cinryze’/exp
#12 ‘complement component c1s inhibitor’
#13 ‘berinert’
#14 ‘conestat alfa’
#15 ‘ruconest’
#16 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
OR #14 OR #15
#17 #6 AND #16
#18 #17 AND (‘conference abstract’/it OR ‘confer-
ence paper’/it OR ‘review’/it)
#19 #17 NOT #18
#20 #17 NOT #18 AND [English]/lim AND [humans]/
lim
PubMed search criteria:
‘‘hereditary angioedema’’[All Fields] AND (‘‘larynx’’
[MeSH Terms] OR ‘‘larynx’’[All Fields] OR ‘‘laryngea-
l’’[All Fields]) NOT acquired[All Fields] AND ((‘‘ecal-
lantide’’[Supplementary Concept] OR ‘‘ecallantide’’[All
Fields]) OR ‘‘C1 inhibitor’’[All Fields] OR (‘‘icatibant’’
[Supplementary Concept] OR ‘‘icatibant’’[All Fields])
OR (‘‘SERPING1 protein, human’’[Supplementary
Concept] OR ‘‘SERPING1 protein, human’’[All Fields]
OR ‘‘cinryze’’[All Fields]) OR berinert[All Fields]
OR (‘‘conestat alpha’’[Supplementary Concept] OR
‘‘conestat alpha’’[All Fields] OR ‘‘ruconest’’[All
Fields])) AND english[Language] NOT review[Publica-
tion Type]
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